SW-579 Cells

Categories: Head-Neck cancer cell lines Description: SW-579 is a human thyroid squamous cell carcinoma cell line, commonly used in cancer research to study thyroid cancer progression and invasiveness. This cell line has been particularly valuable in research exploring the role of matrix metalloproteinases (MMPs) and integrins in cancer cell invasion. Studies involving SW-579 have demonstrated that bone sialoprotein (BSP) significantly enhances the invasiveness of these cells by forming a trimolecular complex with MMP-2 and integrin alphavbeta3. This complex promotes cancer cell movement through extracellular matrices, mimicking the invasive behavior of metastatic cancers. In vitro experiments using a modified Boyden chamber invasion assay have shown that treating SW-579 cells with BSP increased their invasiveness by approximately 10-fold compared to untreated controls. This enhanced invasiveness was found to be mediated by MMP-2 and integrin alphavbeta3, as blocking either the integrin or MMP-2 significantly reduced the effect. These findings highlight the critical role of MMPs and integrins in the metastatic potential of thyroid cancers, making SW-579 a useful model for studying targeted therapies aimed at disrupting these pathways. Moreover, the involvement of BSP in SW-579 cell invasiveness suggests potential therapeutic targets for inhibiting metastasis in thyroid carcinoma. By interfering with the formation of the BSP-MMP-2-integrin alphavbeta3 complex, researchers may be able to reduce the invasiveness of these cancer cells, offering a promising approach to limiting the spread of thyroid cancer in patients. Organism: Human Tissue: Thyroidea Disease: Squamous cell carcinoma Synonyms: SW579, SW 579 Age: 59 years Gender: Male Ethnicity: Caucasian Morphology: Epithelial-like Growth Properties: Monolayer, adherent Citation: SW-579 (Cytion catalog number 300346) Biosafety Level: 1 Ncbi_ Taxid: 9606.0 Cellosaurus Accession: CVCL_3603 Antigen Expression: blood type O, Rh+ Isoenzymes: Me-2, 1-2, PGM3, 1, PGM1, 1-2, ES-D, 1, AK-1, 1, GLO-1, 2, G6PD, B, Phenotype Frequency Product: 0.0209 Oncogenes: myc +, myb + , ras +, fos +, sis +, p53 +, abl -, ros -, src -, N-myc -. Tumorigenic: Yes, produces a grade III malignant spindle and giant cell tumor in nude mice Culture Medium: RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) Supplements: Supplement the medium with 10% FBS Dissociation Reagent: Accutase Subculturing: Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. Fluid Renewal: 2 to 3 times per week Freeze Medium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Thawing And Culturing Cells: Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks, for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes. Sterility: Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. Safety Precautions: When planning to store a cryovial in liquid nitrogen for future thawing, it is mandatory to adhere to stringent safety measures. Appropriate protective gloves and clothing are essential, and the use of a face mask or safety goggles is required during the transfer of frozen samples to or from the liquid nitrogen tank. This is to mitigate the risk of injury from potential cryovial explosions upon removal, which can result in the projection of sharp fragments. Warranty: We stand by the promise of delivering products with high cell viability and robust culture performance. To achieve the best results, please make sure you follow the storage and culture instructions detailed in the product information sheet closely. Your adherence to these guidelines is key to success. Subject To Material Transfer Agreements: If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement. Required Product 1: 820700a Required Product 3: 860015.0 Required Product 4: 830100.0